September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer, redirecting attention toward advances in biomarker testing methodologies.
Read More
FDA Grants Fast Track Designation to Onivyde in Small Cell Lung Cancer
December 1st 2020The FDA has granted a Fast Track designation to the irinotecan liposome injection as a potential treatment option for patients with small cell lung cancer who progressed following a first-line platinum-based regimen, Ipsen announced, in a press release.
Read More
Many Oncologists Favor Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLC
November 21st 2020During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.
Read More
Spigel Applauds Latest Advances to the Treatment Paradigm During Lung Cancer Awareness Month
November 20th 2020During Lung Cancer Awareness Month, David Spigel, MD, shared his insights on the evolving treatment paradigm in lung cancer and how the latest advances have impacted his treatment decisions for patients with lung cancer.
Read More
‘State of Lung Cancer’ Report Reveals Worse Outcomes in Patients of Color
November 18th 2020Patients of color who were diagnosed with lung cancer were associated with worse outcomes compared with Caucasian patients, according to findings from the 3rd Annual “State of Lung Cancer” Report by the American Lung Association.
Read More
Tislelizumab Meets Overall Survival End Point in Phase 3 Study of Advanced NSCLC
November 17th 2020The primary end point of overall survival with tislelizumab compared with docetaxel as the second- or third-line treatment of patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.
Read More
A Long-Term Survival Picture Emerges as Follow-up Data From NSCLC Trials Mature
November 16th 2020Dramatic improvements in efficacy outcomes for patients with non–small cell lung cancer have been a reason for celebration over the last decade, as FDA approvals of immunotherapy-plus-chemotherapy combinations as well as oncogenic-targeting drugs have transformed the treatment landscape.
Read More
Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer
November 9th 2020Alexander Drilon, MD, chief of Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, discussed each of the recently approved agents used for the treatment of these tumors and presented a review of the data at the 15th Annual New York Lung Cancer Symposium.
Read More
COVID-19 Pandemic Creates Teachable Moment for Oncologists in Lung Cancer
November 9th 2020Many challenges have arisen as a result of the coronavirus 2019 pandemic, which is still impacting nations across the world. In the United States, oncologists have initiated research to provide wider understanding of the virus and the threat it poses to patients with lung cancer.
Read More
Testing, Clinical Trial Enrollment Challenges Recognized During Lung Cancer Awareness Month
November 9th 2020In an interview with Targeted Oncology, David M. Waterhouse, MD, MPH, discussed the evolving role of genomic testing and related challenges in the lung cancer treatment paradigm as immunotherapies and targeted therapies continue to expand the field.
Read More